AARD at a glance
Aardvark Therapeutics, Inc. (AARD, SEC CIK 1774857) filed its latest 10-K annual report on March 23, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 17, 2026 and Form 4 insider filings as recently as September 11, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Aardvark Therapeutics, Inc. (AARD) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $57.6 million. Diluted EPS was -$2.93.
- As of June 30, 2026, 15 institutional investment managers tracked by SignalX reported holding Aardvark Therapeutics, Inc. (AARD) shares worth $17.0 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Sun Nelson on September 11, 2026 of 62,000 shares at $5.18 per share.
- In the last 90 days, AARD insiders reported 0 open-market purchases ($0) and 2 open-market sales ($395K) on Form 4, a net sale of $395K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $0
- −100.0% vs prior year
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$395K
- 13F holders
- 15 funds
- $17.0M · −5 vs prior quarter
- Latest 8-K
- Aug 17, 2026
- Item 5.07
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- Newly triggered clinical risk: reversible cardiac observations paused HERO, OLE, POWER, and STRENGTH trials in February 2026
- Most materially updated development risk: FDA full clinical hold on ARD-101 IND in May 2026, followed by HERO and OLE termination in June 2026
- Regulatory risk: future ARD-101 development depends on FDA discussions after program-wide data unblinding and safety-strategy updates
- Operational risk: ARD-101 dependence intensified as terminated PWS trials will not resume as previously designed
- Financial risk: $73.9 million cash, cash equivalents, and short-term investments fund projected operations into late 2027
AI summary of the AARD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.07: Submission of Matters to a Vote of Security Holders
- 54.79% quorum, with 11,992,479 of 21,884,158 shares represented at the meeting
- Victor Tong Jr. and Jeffrey Chi, Ph.D. elected Class I directors through the 2029 annual meeting
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Business updates issued August 11, 2026
Item EX-99.1: Item EX-99.1
- Q2 2026 results: $14.4M net loss, or $0.66 per share, unchanged from Q2 2025
- Cash, equivalents and short-term investments totaled $73.9M, supporting projected operations into late 2027
Item 5.02: Departure/Appointment of Directors or Principal Officers
- CFO/COO Nelson Sun eligible for $346,500 retention payment on January 1, 2027
- CMO Manasi Jaiman eligible for $357,000 retention payment on January 1, 2027
AI summaries of AARD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AARD
Don't miss the next AARD filing
- Alerts as it files. A push when AARD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AARD, by share count.
- Ask anything. An AI agent that reads every AARD filing and answers with sources.
AARD alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Sun Nelson | Sell | Sep 11, 2026 | 62,000 | $5.18 |
| Sun Nelson | Sell | Sep 10, 2026 | 14,754 | $5.00 |
| Tong Victor Edward Jr | A | Aug 14, 2026 | 44,964 | - |
| Graf Susan E | A | Aug 14, 2026 | 44,964 | - |
| Chi Jeffrey | A | Aug 14, 2026 | 44,964 | - |
| Baynes Roy D. | A | Aug 14, 2026 | 44,964 | - |
| Lee Tien-Li | A | Feb 9, 2026 | 203,851 | - |
| Jaiman Manasi | A | Feb 9, 2026 | 70,549 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $2.4M | $0 |
| Operating Income | - | -$22.8M | -$62.7M |
| Net Income | - | -$20.6M | -$57.6M |
| Op. Margin | - | -943.9% | - |
| Net Margin | - | -852.9% | - |
| Balance Sheet | |||
| Total Assets | - | $77.5M | $117.2M |
| Equity | -$34.8M | -$54.6M | $106.6M |
| ROE | - | 37.7% | -54.0% |
| Per Share | |||
| EPS | - | $-5.15 | $-2.93 |
| Cash Flow | |||
| Operating CF | - | -$18.1M | -$54.2M |
| CapEx | - | $109K | $95K |
Source: XBRL data in Aardvark Therapeutics, Inc. (AARD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate AARD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 15 | $17.0M |
| Q1 2026 | 20 | $13.5M |
| Q4 2025 | 15 | $50.6M |
| Q3 2025 | 16 | $38.5M |
| Q2 2025 | 11 | $28.1M |
| Q1 2025 | 9 | $11.6M |
- AQR Capital Management+345.8K (+257%)
- Raymond James Financial+68.4K (+628%)
- Citadel Advisors LLC+40.4K (+3%)
- Morgan Stanley+12.6K (+72%)
- FMR LLC (Fidelity)+9.9K (+111%)
- BlackRock−605.5K (-76%)
- State Street Corp−140.0K (-70%)
- Northern Trust−60.5K (-68%)
- Two Sigma Investments−55.0K (-34%)
- Millennium Management−28.4K (-29%)
- Vanguard Portfolio Management LLC−75.1K
- Renaissance Technologies LLC−70.8K
- BNY Mellon−29.3K
- Bank of America Corp−11.5K
- Wells Fargo & Co−4.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 86 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AARD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 11, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 8-K | Aug 17, 2026 | - | Analysis | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 8-K | May 14, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 8-K | Mar 24, 2026 | - | - | - |
| 8-K | Mar 23, 2026 | - | - | - |
| 10-K | Mar 23, 2026 | Dec 31, 2025 | - | |
| 8-K | Feb 27, 2026 | - | Analysis | - |
| 8-K | Feb 12, 2026 | - | - | |
| 4 | Feb 11, 2026 | - | - | |
| 4 | Feb 11, 2026 | - | - | |
| 4 | Feb 11, 2026 | - | - | |
| 8-K | Feb 10, 2026 | - | - | |
| 8-K | Jan 12, 2026 | - | - | |
| 4 | Dec 12, 2025 | - | - | |
| 4 | Dec 12, 2025 | - | - | |
| 8-K | Dec 10, 2025 | - | - |
Related Health Care companies
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
- ACET · Adicet Bio IncPharmaceutical Preparations
AARD SEC filings: frequently asked questions
Are AARD insiders buying or selling?
In the last 90 days, Aardvark Therapeutics, Inc. (AARD) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $394,957 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold AARD stock?
As of June 30, 2026, the largest Aardvark Therapeutics, Inc. (AARD) holders among the 13F filers tracked by SignalX were Citadel Advisors LLC ($7.4 million), Vanguard Capital Management LLC ($3.2 million), AQR Capital Management ($2.8 million), BlackRock ($1.1 million), Two Sigma Investments ($624,000). 13F-HR reports are filed up to 45 days after each quarter ends.
What was AARD's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Aardvark Therapeutics, Inc. (AARD) reported revenue of $0 (down 100.0% from FY2024) and a net loss of $57.6 million. Diluted EPS was -$2.93. The figures come from the XBRL data in the 10-K.
What did AARD report in its latest 8-K?
Aardvark Therapeutics, Inc. (AARD) filed an 8-K on August 17, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). 54.79% quorum, with 11,992,479 of 21,884,158 shares represented at the meeting.
What are the latest AARD SEC filings?
Aardvark Therapeutics, Inc. (AARD) filed its latest 10-K annual report on March 23, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on August 17, 2026 and a Form 4 insider filing on September 11, 2026.
What is AARD's SEC CIK number?
Aardvark Therapeutics, Inc. (AARD)'s SEC Central Index Key (CIK) is 1774857. EDGAR lists every AARD filing under that number.
Ask anything about AARD
The research agent reads AARD's filings, financials, insider trades and 13F holders, then answers with sources.